Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Market Cap	5.85B
Revenue (ttm)	165.70M
Net Income (ttm)	-165.70M
Shares Out	788.62M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,587,400
Average Volume	7,690,550
Open	7.44
Previous Close	7.42
Day's Range	7.31 - 8.22
52-Week Range	1.20 - 9.55
Beta	0.62
RSI	54.98
Earnings Date	Aug 27, 2025

About HKG:1167

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under multiple stage studies for indications such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications including NSCLC, PDAC, CRC, and other solid tumors; JAV-8263, a BET inhibitor for so...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 257
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1167

Financial Performance

In 2024, HKG:1167's revenue was 155.71 million, an increase of 145.13% compared to the previous year's 63.52 million. Losses were -155.71 million, -56.64% less than in 2023.

Financial numbers in CNY